Literature DB >> 31392583

Anticholinergic and sedative medications exposure in older patients: a cross-sectional study.

Xiaolin Zhang1, Shuang Zhou2, Xinran Li2, Weiwei Zhou1, Ying Zhou2, Yimin Cui2, Xinmin Liu3.   

Abstract

Background The Drug Burden Index is a risk assessment tool used to quantify anticholinergic and sedative medications burden of older patients. There have been no previously published reports the exposure of anticholinergic and sedative medications in China. Objective We investigated the prevalence and correlates risk factors of anticholinergic and sedative medications in hospitalized older patients with polypharmacy in China. Settings The Department of Geriatrics in a tertiary care teaching hospital. Methods A retrospective analysis of patient medical records of hospitalized older patients with polypharmacy was undertaken at a large university teaching hospital in China. Polypharmacy was defined as the regular use of more than five medications. Prescribing of anticholinergic and sedative medications was identified using the medication list of the Drug Burden Index, and logistic regression analysis determined associations between drug exposure and independent variables. Main outcome measure Anticholinergic and sedative medications identified by the Drug Burden Index. Results A total of 383 patients were included in this study, with an average age of 82.6 ± 7.0 years and included 72.9% (279/383) male patients. Of the study participants, 23.8% (91/383) were prescribed anticholinergic and sedative medications. Of the 106 medicines identified by the Drug Burden Index, the most frequently prescribed medications were estazolam in 51.9% (55/106), terazosin in 14.1% (15/106), loratadine in 10.4% (11/106), and cetirizine in 5.7% (6/106); these four medications accounted for 82.1% of the anticholinergic and sedative medications. Drug exposure was associated with age ≥ 80 years (OR 2.246; 95% CI 1.100-4.586), the number of prescribed medications (OR 1.102; 95% CI 1.018-1.193), and symptoms of insomnia (OR 28.990; 95% CI 14.197-59.200). Conclusions The findings of this study showed that the prevalence of anticholinergic and sedative exposure in hospitalized older patients with polypharmacy in China. The prevalence of exposure of anticholinergic and sedative medications was 23.8%. According to the Drug Burden Index estazolam and terazosin were the most common medications in the sedative or anticholinergic drug class, respectively.

Entities:  

Keywords:  Anticholinergic effects; China; Drug Burden Index; Polypharmacy; Sedatives

Mesh:

Substances:

Year:  2019        PMID: 31392583     DOI: 10.1007/s11096-019-00885-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  27 in total

1.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

Review 2.  Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

Authors:  Jennifer Glass; Krista L Lanctôt; Nathan Herrmann; Beth A Sproule; Usoa E Busto
Journal:  BMJ       Date:  2005-11-11

Review 3.  Clinical consequences of polypharmacy in elderly.

Authors:  Robert L Maher; Joseph Hanlon; Emily R Hajjar
Journal:  Expert Opin Drug Saf       Date:  2013-09-27       Impact factor: 4.250

4.  Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults.

Authors:  Lydia Rolita; Adele Spegman; Xiaoqin Tang; Bruce N Cronstein
Journal:  J Am Geriatr Soc       Date:  2013-03-01       Impact factor: 5.562

5.  A drug burden index to define the functional burden of medications in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Arch Intern Med       Date:  2007-04-23

Review 6.  Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.

Authors:  Iacopo Cancelli; Massimiliano Beltrame; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Neurol Sci       Date:  2009-02-20       Impact factor: 3.307

Review 7.  Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms.

Authors:  Matthias Oelke; Adrian Gericke; Martin C Michel
Journal:  Expert Opin Drug Saf       Date:  2014-07-29       Impact factor: 4.250

Review 8.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.

Authors:  Denis O'Mahony; David O'Sullivan; Stephen Byrne; Marie Noelle O'Connor; Cristin Ryan; Paul Gallagher
Journal:  Age Ageing       Date:  2014-10-16       Impact factor: 10.668

9.  Patients Aged 80 Years or Older are Encountered More Potentially Inappropriate Medication Use.

Authors:  Li Mo; Ding Ding; Shi-Yun Pu; Qin-Hui Liu; Hong Li; Bi-Rong Dong; Xiao-Yan Yang; Jin-Han He
Journal:  Chin Med J (Engl)       Date:  2016-01-05       Impact factor: 2.628

10.  Association between sedating medications and delirium in older inpatients.

Authors:  Michael B Rothberg; Shoshana J Herzig; Penelope S Pekow; Jill Avrunin; Tara Lagu; Peter K Lindenauer
Journal:  J Am Geriatr Soc       Date:  2013-04-30       Impact factor: 7.538

View more
  3 in total

Review 1.  An Update on Medication Use in Older Adults: a Narrative Review.

Authors:  Heather E Barry; Carmel M Hughes
Journal:  Curr Epidemiol Rep       Date:  2021-07-20

2.  Anti-Cholinergic Drug Burden Among Ambulatory Elderly Patients in a Nigerian Tertiary Healthcare Facility.

Authors:  Joseph O Fadare; Abimbola Margaret Obimakinde; Felix O Aina; Ebisola J Araromi; Theophilus Adekunle Adegbuyi; Oluwatoba E Osasona; Tosin A Agbesanwa
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

3.  Older adults' exposure to anticholinergic medications: Implications for pharmaceutical care for Nigerian older adults.

Authors:  Roland Nnaemeka Okoro; Algoni Idris Idris
Journal:  J Med Access       Date:  2022-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.